CF

CARLA FALASCO

BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.) · WASHINGTON, DC · registered since 2024
Registered · LDAActive

At a glance

Registered since
2024
Senate LDA system
Clients
1
last 3 years
Filings
1
2 agencies contacted
Activity
filings by quarter
Works on

Background

Career

Specific issues

-H.R 8698, SCREEN for Type 1 Diabetes Act (A bill to amend the Public Health Service Act to provide for a public awareness campaign with respect to screening for type 1 diabetes, and for other purposes). -S. 4504, SCREEN Act (A bill to amend the Public Health Service Act to provide for a public awareness campaign with respect to screening for type 1 diabetes, and for other purposes). -S. 1269, INSULIN Act of 2023. -S. 1855, Special Diabetes Program Reauthorization Act of 2023. -H.R. 2550, Special Diabetes Program Reauthorization Act of 2023. -H.R 1499, Affordable Insulin Now Act. -S. 954, Affordable Insulin Now Act of 2023. -H.R. 5378, Lower Costs, More Transparency Act. -H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023. -Issues related to cell and gene therapies.
Health Issues · 2024 Q2
H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025.
Budget/Appropriations · 2024 Q2

Clients

$██,███ / qtrUnlock

Filing history

2024 Q2
BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)
Q2lda.gov →
Showing recent filings · full history on lda.gov